[en] GH-secreting pituitary adenomas can be hypo-, iso- or hyperintense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyperintense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypointense adenoma had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyperintense groups (p<0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypointense group (38%) compared with the T2-iso- and hyperintense groups (8% and 3%, respectively; p<0.0001). The response to SSA correlated with the calculated T2-intensity: the lower the T2-weighted intensity, the greater the decrease of random GH (p<0.0001, r=0.22), IGF-1 (p<0.0001, r=0.14) and adenoma volume (p<0.0001, r=0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with the hormone reduction and tumor shrinkage in response to primary SSA treatment in acromegaly. This study supports its use as a generally available predictive tool at diagnosis that could help to guide subsequent treatment choices in acromegaly.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Potorac, Iulia ; Université de Liège - ULiège > Doct. sc. médicales (Bologne)
PETROSSIANS, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
Daly, Adrian ; Université de Liège > Département des sciences cliniques > Endocrinologie
Alexopoulou, Orsalia
Borot, Sophie
Sahnoun Fathallah, Mouna
Castinetti, Frederic
Devuyst, France
Jaffrain Rea, Marie-Lise
Briet, Claire
Luca, Florina
Lapoirie, Marion
Zoicas, Flavius
Simoneau, Isabelle
Diallo, Alpha
Muhammad, Ammar
Kalestimur, F
Nazzari, Elena
Garcia Centeno, Rogelio
Webb, Susan M.
Nunes, Marie-Laure
Hana, Vaclav
Pascal-Vigneron, Veronique
Ilovayskaya, Irena
Nasybullina, Farida
Achir, Samia
Ferone, Diego
Neggers, Sebastian
Delemer, Brigitte
Petit, Jean-Michel
Schoefl, Christof
Raverot, Gerald
Goichot, Bernard
Rodien, Patrice
Corvilain, Bernard
Brue, Thierry
Schillo, Franck
TSHIBANDA, Luaba ; Centre Hospitalier Universitaire de Liège - CHU > Service médical de radiodiagnostic
Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB & Wass JA 1999 Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology 50 561-567. (doi:10.1046/j.1365-2265.1999.00760.x)
Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A & Jaquet P 1998 Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. Journal of Clinical Endocrinology and Metabolism 83 1604-1610. (doi:10.1210/jc.83.5.1604)
Beckers A, Lodish M, Trivellin G, Rostomyan L, Lee M, Faucz FR, Yuan B, Choong C, Caberg JH, Verrua E et al. 2015 X-linked acrogigantism (X-LAG) syndrome: Clinical profile and therapeutic responses. Endocrine-Related Cancer 22 353-367. (doi:10.1530/ERC-15-0038)
Bevan JS 2005 Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 90 1856-1863. (doi:10.1210/jc.2004-1093)
Bhayana S, Booth GL, Asa SL, Kovacs K & Ezzat S 2005 The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 90 6290-6295. (doi:10.1210/jc.2005-0998)
Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN & Melmed S 2015 A structural and functional acromegaly classification. Journal of Clinical Endocrinology and Metabolism 100 122-131. (doi:10.1210/jc.2014-2468)
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A 2006 High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 91 4769-4775. (doi:10.1210/jc.2006-1668)
Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A et al. 2010 Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study. Journal of Clinical Endocrinology and Metabolism 95 E373-E383. (doi:10.1210/jc.2009-2556)
Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G, Sosa E & Mercado M 2015 Octreotide LAR treatment of acromegaly in 'real life': Long-term outcome at a tertiary care center. Pituitary 18 290-296. (doi:10.1007/s11102-014-0570-0)
Fernandez A, Karavitaki N & Wass JA 2010 Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 72 377-382. (doi:10.1111/j.1365-2265.2009.03667.x)
Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW & Hofland LJ 2008 Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. Journal of Clinical Endocrinology and Metabolism 93 1412-1417. (doi:10.1210/jc.2007-1358)
Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F et al. 2008 Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 93 2746-2750. (doi:10.1210/jc.2008-0126)
Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T & Miyamoto T 2003 Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: Imaging characteristics and pathologic correlation. Radiology 228 533-538. (doi:10.1148/ radiol.2282020695)
Heck A, Emblem KE, Casar-Borota O, Bollerslev J & Ringstad G 2015 Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52 333-343. (doi:10.1007/s12020-015-0766-8)
Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J & Bollerslev J 2012 Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology 77 72-78. (doi:10.1111/j.1365-2265. 2011.04286.x)
Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F et al. 2016 Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study. European Journal of Endocrinology 174 241-250. (doi:10.1530/EJE-15-0832)
Jaffrain-Rea M-L, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen J-F, D'Innocenzo E, Barlier A, Giangaspero F, Esposito V et al. 2009 Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: Pathological and clinical implications. Endocrine-Related Cancer 16 1029-1043. (doi:10.1677/ERC-09-0094)
Jallad RS, Musolino NR, Kodaira S, Cescato VA & Bronstein MD 2007 Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?. Clinical Endocrinology 67 310-315. (doi:10.1111/j.1365-2265.2007.02885.x)
Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE & Wass JA 2006 Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition?. A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clinical Endocrinology 65 524-529. (doi:10.1111/j.1365-2265.2006.02627.x)
Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ & Wass JA 2008 Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clinical Endocrinology 68 970-975. (doi:10.1111/j.1365-2265.2007.03139.x)
Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM & Gadelha MR 2012 AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocrine-Related Cancer 19 L25-L29. (doi:10.1530/ERC-12-0020)
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A & Wass JA 2014 Acromegaly: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 99 3933-3951. (doi:10.1210/jc.2014-2700)
Lundin P & Pedersen F 1992 Volume of pituitary macroadenomas: Assessment by MRI. Journal of Computer Assisted Tomography 16 519-528. (doi:10.1097/00004728-199207000-00004)
Melmed S 2016 New therapeutic agents for acromegaly. Nature Reviews Endocrinology 12 90-98. (doi:10.1038/nrendo.2015.196)
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA & Wass JA 2011 Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 96 273-288. (doi:10.1210/jc.2010-1692)
Melmed S, Cook D, Schopohl J, Goth MI, Lam KS & Marek J 2010 Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: A randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13 18-28. (doi:10.1007/s11102-009-0191-1)
Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M et al. 2007 A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology 66 859-868. (doi:10.1111/j.1365-2265.2007.02825.x)
Nomikos P, Buchfelder M & Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology 152 379-387. (doi:10.1530/eje.1.01863)
Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P & Beckers A 2005 Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology 152 61-66. (doi:10.1530/ eje.1.01824)
Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, Sahnoun Fathallah M, Brue T, Girard N, Chanson P et al. 2015 Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer 22 169-177. (doi:10.1530/ERC-14-0305)
Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Marti C, Halperin I & Webb SM 2010 Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. Journal of Clinical Endocrinology and Metabolism 95 4973-4978. (doi:10.1210/ jc.2010-0573)
R Core Team 2014 R: A Language and Environment for Statistical Computing. Vienna, Austria: R Core Team.
Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, Lecumberri B, Trivellin G, Salvatori R, Moraitis AG et al. 2015 Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients. Endocrine-Related Cancer 22 745-757. (doi:10.1530/ERC-15-0320)
Sarkar D 2008 Lattice: Multivariate Data Visualization with R. New York, NY, USA: Springer, ISBN 978-0-387-75968-5.
Sarkar S, Rajaratnam S, Chacko G & Chacko AG 2014 Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly. Clinical Neurology and Neurosurgery 126 190-195. (doi:10.1016/ j.clineuro.2014.09.004)
Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH & Jane JA Jr 2013 Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: Outcomes in a concurrent series of patients using modern criteria for remission. Journal of Clinical Endocrinology and Metabolism 98 3190-3198. (doi:10.1210/ jc.2013-1036)
Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P et al. 2008 Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology 158 295-303. (doi:10.1530/EJE-07-0562)
